Department of Infectious Diseases, Hôtel Dieu Hospital, APHP, 1 Place du Parvis Notre-Dame, 75004, Paris, France.
Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), 75004, Paris, France.
BMC Infect Dis. 2023 Feb 17;23(1):98. doi: 10.1186/s12879-023-08071-9.
The use of long acting injectable (LAA) antiretroviral drugs may be an alternative option for HIV treatment and prevention. Our study focused on patient perspectives to understand which individuals, among people with HIV (PWH) and pre-exposure prophylaxis (PrEP) users, would constitute the preferential target for such treatments in terms of expectations, tolerability, adherence and quality of life.
The study consisted in one self-administrated questionnaire. Data collected included lifestyle issues, medical history, perceived benefits and inconveniences of LAA. Groups were compared using Wilcoxon rank tests or Fisher's exact test.
In 2018, 100 PWH and 100 PrEP users were enrolled. Overall, 74% of PWH and 89% of PrEP users expressed interest for LAA with a significantly higher rate for PrEP users (p = 0.001). No characteristics were associated with acceptance of LAA in both groups in term of demographics, lifestyle or comorbidities.
PWH and PrEP users expressed a high level of interest in LAA, since a large majority seems to be in favor of this new approach. Further studies should be conducted to better characterize targeted individuals.
长效注射型（LAA）抗逆转录病毒药物的使用可能是 HIV 治疗和预防的一种替代选择。我们的研究侧重于患者的观点，以了解在期望、耐受性、依从性和生活质量方面，哪些 HIV 感染者（PWH）和暴露前预防（PrEP）使用者是这种治疗的优先目标人群。
该研究包括一个自我管理的问卷。收集的数据包括生活方式问题、病史、对 LAA 的益处和不便的认知。使用 Wilcoxon 秩检验或 Fisher 精确检验比较组间差异。
2018 年，纳入了 100 名 PWH 和 100 名 PrEP 用户。总体而言，74%的 PWH 和 89%的 PrEP 用户对 LAA 感兴趣，PrEP 用户的比例显著更高（p=0.001）。在两组人群中，无论在人口统计学、生活方式还是合并症方面，都没有特征与接受 LAA 相关。
PWH 和 PrEP 用户对 LAA 表达了高度的兴趣，因为大多数人似乎都赞成这种新方法。应该进行进一步的研究，以更好地描述目标人群。
